Coya Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Coya Therapeutics (COYA).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$16Upside to Avg. PT+279.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	BTIG	Thomas Shrader	Maintained	Buy	$16
Aug 24, 2026	Roth Capital	Boobalan Pachaiyappan	Maintained	Buy	$12
Aug 12, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Jun 12, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Jun 5, 2026	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$12
Apr 10, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Mar 19, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Mar 16, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Mar 16, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Feb 18, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Feb 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Jan 21, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Jan 8, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Jan 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Jan 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Dec 23, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Dec 9, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$15
Nov 14, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$14
Nov 13, 2025	BTIG	Thomas Shrader	PT Raise	Buy	$15→$16

Analyst Ratings News

PRO
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target

BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target.

Benzinga Newsdesk

This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONTO rated Buy with $350 PT by Deutsche Bank.

Avi Kapoor

PRO
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $18 price target.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target

D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $15 price target.

Benzinga Newsdesk

Coya Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Coya Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target

PRO
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

PRO
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

PRO
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target

People Also Watch

People Also Watch

Coya Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Coya Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target

PRORoth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRORoth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

PROHC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

PROD. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target

PRO
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

PRO
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

PRO
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

PRO
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target